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Abbreviations 
DMEM – Dulbecco’s Modified Eagle’s Medium 
EDTA - Ethylenediaminetetraacetic acid 
FCS - Foetal calf serum 
GPCR – G protein coupled receptor 
mAB – monoclonal antibody 
n.s. – non significant 
PBS - Phosphate buffered saline 
PKC - Protein kinase c 
S.E.M. – Standard Error of Means 
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Abstract 
Chemotaxis or directed cell migration is mediated by signalling events initiated by binding of 
chemokines to their cognate receptors and the activation of a complex signalling cascade. 
The molecular signalling pathways involved in cell migration are important to understand 
cancer cell metastasis. Therefore we investigated the molecular mechanisms of CXCL12 
induced cell migration and the importance of different signalling cascades that become 
activated by CXCR4 in leukemic cells versus breast cancer cells. We identified Src kinase as 
being essential for cell migration in both cancer types, with strong involvement of the 
Raf/MEK/ERK1/2 pathway. We did not detect any involvement of Ras or JAK2/STAT3 in 
CXCL12 induced migration in Jurkat cells. Preventing PKC activation with inhibitors does not 
affect migration in Jurkat cells at all, unlike in the adherent breast cancer cell line MCF-7 cells. 
However in both cell lines, knock down of PKCα prevents migration towards CXCL12, whereas 
the expression of PKCζ is less crucial for migration. PI3K activation is essential in both cell 
types, however LY294002 usage in MCF-7 cells does not block migration significantly. These 
results highlight the importance of verifying specific signalling pathways in different cell 
settings and with different approaches.  
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1. Introduction 
Tumour metastasis is the major cause of death in cancer patients who have suffered a primary 
solid tumour or haematological malignancy. The chemokine CXCL12 along with Src and 
P13K/Akt signalling appears to be implicated in both breast cancer metastatic progression to 
bone and other tissues, and leukaemia reoccurrence [1-4]. Metastasis results from a 
sequential series of processes, in which tumour cells undergo epithelial-mesenchymal 
transition. Cells detach from the original tumour tissue, intravasate into blood vessels, survive 
and travel along the circulation, extravasate to secondary organs, transform back to the 
epithelial state, and proliferate at their new location [5-7]. Recent data indicates that 
chemotactic signalling plays a crucial role in tumour invasion and spreading [8-14]. 
Chemotaxis is mediated by signalling events initiated by binding of chemokines to their 
cognate receptors, and involves re-arrangement of the actin cytoskeleton. CXCL12 can bind 
the G-protein coupled receptor CXCR4 causing Gαi triggered adenylate cyclase inhibition and 
hence a reduction in cAMP levels in the cell. This mediates the Src kinase phosphorylation 
cascade, which leads to ERK activation, Rho triggered actin rearrangement, cell polarisation 
and finally migration down a chemokine gradient [15]. Chemokine induced chemotaxis is key 
in homeostasis; for example CXCL12 is essential in lymph tissues and for movement of 
haematopoietic cells between blood and bone marrow [15, 16]. CXCR4 has been the subject 
of much scrutiny, since it has been implicated in the metastasis of various cancers (1,7,8,). 
For example, CXCL12 has been shown to be detrimental in the movement of blasts in 
leukaemia [17] and CXCL12+ cells are implicated in the formation of bone metastasis following 
breast cancer [18]. However the signal networks that are important for chemokine receptor 
triggered cell migration and metastasis are not yet completely understood due to their 
complexity. Nevertheless for CXCR4 signalling, concentrations and gradients of CXCL12 are 
purportedly important. Excess CXCL12 may further damage tissues suffering insult from 
ischaemia, toxins, chemotherapeutic agents and atherosclerosis [15]. CXCL12 levels tend to 
rise with age [19] and excess concentrations may inhibit metastasis [20]. Many chemokines 
bind several chemokine receptors and CXCL12 binds CXCR4 and CXCR7. It appears CXCR7 
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activities include acting as a scavenger, modulating the levels of CXCL12 in the vicinity of cells 
carrying the receptor, and that binding of CXCL12 to CXCR7 may cause internalisation of the 
receptor without resulting in downstream signalling [21-23]. Over the years various signalling 
molecules that are involved in CXCR4 triggered migration have been identified, however there 
is still some uncertainty about which pathways are directly involved in cell migration. For 
CXCR4 it has been shown that migration under certain circumstances is dependent on β-
arrestins as well as filamin-A, a protein, which can bind actin and interacts with β-arrestins 
[24-26]. Several groups have shown that ERK1/2 or p38 MAPK activation is important for cell 
migration as well [13, 27]. Similarly, Protein Kinase Cε (PKCε) activation has been shown to 
be implicated in the movement of T cells [28] and atypical Protein Kinase Cζ (PKCζ) is directly 
involved in CXCL12 signalling in immature human CD34(+)-enriched cells and in leukemic 
pre-B acute lymphocytic leukaemia (ALL) G2 cells [29]. There is still some discussion whether 
JAK kinase activity is needed for migration or not, with some reports showing that in murine 
neural progenitor cells JAK activation is not necessary [30] whereas in metastatic T-lymphoma 
JAK activation is essential for migration [31]. Of particular interest in this respect is a study by 
Pfeiffer et al [32] where the JAK2 inhibitor AG490 only inhibited CXCL12 induced adhesion in 
NCI-H82 and not in NCI-H69 cells. These data show that the signalling networks which are 
used by CXCL12 and its receptor CXCR4 probably vary between different species and cell 
types. Subsequently, we determined in this study whether the pharmacological blockade of 
different signalling cascades like the MEK/ERK1/2 kinase cascade or JAK/STAT differentially 
block CXCL12 induced cell migration in leukemic cells versus adherent breast cancer cells. 
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2. Materials and Methods 
2.1 Cells and materials 
The leukemic cell line Jurkat was obtained from the ATCC and grown in RPMI containing 10% 
FCS and 2 mM L-glutamine. The breast cancer cell line MCF-7 was obtained from the ATCC 
and grown in DMEM containing 10% FCS and 2 mM L-glutamine. The chemokine CXCL12 
was obtained from Peprotech. JAK inhibitor 2 (1,2,3,4,5,6-Hexabromocyclohexane, JAK-2) 
and STAT3 inhibitor VIII, 5,15-DPP (STAT3 VIII) were from Calbiochem. LY294002, AG490, 
Bosutinib, Rottlerin, GF109203X, Staurosporine and CID755673 were purchased from Tocris. 
Farnesyl thiosalicylic acid (FTS), SB203580, PD98059, L775450, FH535 and SL327 were 
from Abcam. Cells were treated with 10 µM LY294002, 50 µM JAK2, 50 µM STAT3 VIII, 5 µM 
GF109203X, 10 nM Staurosporine, 11 µM CID755673, 10 µM AG490, 5 µM Bosutinib, 12.5 
µM FTS, 10 µM SB203580, 12.5 µM & 25 µM PD98059, 0.5 & 1 µM L775450, 1 µM FH535, 1 
µM SL327 and 4µM Rottlerin for 30 minutes before induction of chemotaxis. Anti-CXCR4 
antibody 12G5 was from Santa Cruz and the corresponding goat anti-mouse FITC labelled 
secondary antibody came from Sigma Aldrich. Anti-PKCα (H-7), anti-PKCζ and β-actin 
antibodies were purchased from Santa Cruz. Anti-Src and anti-Pi3K p85 were from Biotechne 
and the mouse peroxidase labelled secondary antibodies were from Sigma Aldrich. All other 
chemicals were obtained from Fisher Scientific.  
 
2.2 Chemotaxis Assays 
Cells were harvested and then resuspended at a concentration of 25x104 cells mL-1 in serum-
free RPMI 1640 containing 0.1% BSA. Cells were loaded in a total volume of 20 µL into the 
upper compartment of a microchemotaxis chamber (Receptor Technologies, Adderbury, UK). 
For inhibitor treatment, cells were incubated for 30 minutes with the relevant inhibitors or 
vehicle control before loading onto the membrane. Chemoattractants at a concentration of 1 
nM were loaded in a final volume of 31 µL at indicated concentrations in the lower 
compartment. The two compartments were separated by a polyvinylpyrollidone-free 
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polycarbonate filter with 5 µm pores. The chemotaxis chamber was incubated at 37°C, 100% 
humidity, and 5% CO2 for 4 h. The filter was then removed, and the number of cells migrating 
into each bottom compartment was counted using a haemocytometer. In all experiments, each 
data point was performed in duplicate. 
 
2.3 Wound healing assays: 
MCF-7 cells were seeded onto 24 well plates overnight. After 24 hours, the cells were washed 
once in DMEM without supplements and incubated in DMEM without supplements. A scratch 
was introduced to the monolayer with 200 µL pipette tips (time point 0). Inhibitors were added 
to the cells and incubated for 30 minutes at 37°C, 100% humidity, and 5% CO2. Chemokines 
or vehicle controls were added to the cells and pictures were taken at timepoint 0 and after 24 
hours using an inverted Leica microscope. Images were analysed and the width of the wound 
was measured for control and with inhibitor treatment (with and without chemokine) at 0 hours 
and 24 hours. The ratio of the width of the wound after 24 hours divided by the width of the 
wound at 0 hours can then be used compare the effectiveness of treatments in preventing 
migration, where a number of 1 denotes no migration and a number smaller than 1 denotes 
migration of cells. 
 
2.4 Cell Viability Studies 
MTS assays were performed using a CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega). 100 µL wells containing 5x105 cells mL-1 in complete RPMI 
supplemented with the test compounds at working concentrations were maintained at 37°C 
and 5% CO2 for 2 hours in a humidified atmosphere. After incubation, cell viability was 
assessed using the CellTiter 96® AQueous One Solution Cell Proliferation Assay. The 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
tetrazolium compound is bioreduced by cells into a coloured formazan product that is soluble 
in tissue culture medium [33]. This conversion is presumably accomplished by NADPH or 
NADH produced by dehydrogenase enzymes in metabolically active cells [34]. Aliquots of 10 
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µL of the CellTiter 96® AQueous One Solution Reagent were added directly to the wells and 
the plates were incubated for 4 hours at 37 °C in a humidified atmosphere, 5% CO2 and then 
absorbance at 490 nm was read with a 96-well plate reader. The quantity of formazan product 
as measured by the absorbance at 490 nm is directly proportional to the number of living cells 
in culture. The inhibitors were used at concentrations which did not show any toxic effects over 
a 5 hour incubation period. 
 
2.5 Immunofluorescence staining 
The Jurkat cell line was washed in PBS and re-suspended at a concentration of 5 x 106 cells/ml 
in PBS and were incubated at 4°C with CXCR4 mAB 12G5 or isotype control for 1 h. Cells 
were washed twice in cold PBS staining was performed using fluorescein isothiocyanate 
(FITC) labelled donkey anti-mouse immunoglobulin secondary antibodies (1:100, Sigma 
Aldrich) for 1 h at 4°C. Cells were then washed in PBS and dropped onto a glasslide and 
pictures taken with an inverted Leica DMII fluorescence microscope. MCF-7 cells were seeded 
on coverslips overnight, washed with PBS and stained with 12G5 or isotype control as 
described above.  
 
2.6 siRNA transfection 
PKCα, PKCζ siRNA and scrambled siRNA were obtained from Qiagen (Hilden, Germany), 
PI3K and Src siRNA were obtained from GE Healthcare (UK) and diluted to working 
concentrations in RNAse free water. Jurkat cells were transfected with 50 nM scrambled 
siRNA, 50 nM PKCα or PKCζ siRNA or vehicle, respectively, using the Amaxa Nucleofector 
according to manufacturer’s instructions. In short 3X106 cells per cuvette were used for the 
transfection and after 48 hours a chemotaxis assay was performed. The MCF-7 cells were 
transfected using Lipofectamine RNAi (ThermoFisher Scientific) according to manufacturer’s 
instruction.  
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2.7 SDS–PAGE and Western blot.  
Cells were harvested and then resuspended in Mammalian Protein Extraction Buffer (GE 
Healthcare) at 4 °C for 40 minutes with gentle mixing. Analysis of the proteins on SDS–PAGE 
was done as described [35]. Antibodies were removed from the membrane before a second 
stain by incubation with Millipore Stripping Solution (Millipore, Temecula California) at room 
temperature for 15 minutes before blocking and reprobing. 
 
2.8 Analysis of data 
Data were analysed using GraphPad Prism (GraphPad Software). Statistical analyses were 
performed using an One-way ANOVA with a Bonferroni Multiple Comparison test as post-test 
with a p value <0.05. Data represent the mean ± s.e.m. of at least three independent 
experiments. 
 
3. Results 
3.1 PKC activation is vital for cell migration in breast cancer cell, but less so in leukemic 
cells 
CXCR4 induced cell migration is depending on a plethora of intracellular proteins, which need 
to become activated to allow the cell to move towards the chemokine stimulus. Here we 
investigated different signalling cascades and whether they are implicated in CXCR4 migration 
in suspension cells versus adherent cells. We have recently shown that PKC activation is not 
essential for CCL3 induced migration of the suspension cell line THP-1 [36]. In a similar 
fashion, we used two PKC inhibitors which block a wide variety of PKC isoforms 
(Staurosporine and GF109203X) as well as the more specific PKD inhibitor CID755673 and 
Rottlerin, which has been described as a selective PKCδ, but has since been found to block 
other kinases and to uncouple mitochondria [37]. All four inhibitors used did not block migration 
in Jurkat cells induced by CXCL12 (Figure 1A - D). The only significant effect was observed 
with Rottlerin, which actually increases the number of cells migrating. However in wound 
 10 
healing assays on the breast cancer cell line MCF-7, both Rottlerin and GF109203X exhibit 
the opposite effect. In these cells, they prevent migration of cells into the wound effectively 
after 24 hours (Figure 1E, F). Expression of CXCR4 in both cell lines was confirmed using a 
monoclonal antibody against CXCR4 (Figure 1G). siRNA knockdown of PKCα and PKCζ 
proteins in MCF-7 cells confirmed the importance of PKC for migration in these cells (Figure 
2 A,C), where the loss of PKCα and PKCζ completely abolishes any migration towards 
CXCL12. Whereas transfection of PKCα and PKCζ siRNA into Jurkat cells allows us to 
differentiate between the use of different PKC isoforms. PKCα knockdown leads to a loss of 
about half the migratory response, whereas the PKCζ knockdown has less impact. In both 
cases, there are still a robust number of cells migrating, even though the migration is 
significantly lower than in control cells (transfected with scrambled siRNA) (Figure 2 B,D), 
unlike the MCF-7 cells (Figure 2 A,C), where the knockdown of PKCα and PKCζ completely 
prevents movement of cells into the wound. The success of knockdown was confirmed by 
Western blot analysis (Figure 2 E, F, G). 
 
3.2 JAK2 and STAT3 activation is not necessary for migration of leukemic cells.  
We then investigated whether there are other pathways that are important in cell migration. 
We used inhibitors to block JAK2 and STAT3 activation (Figure 3 A, B), but none blocked 
CXCL12 induced migration in Jurkat cells. Similarly, a Ras inhibitor, Farnesylthiosalicyllic acid, 
did not affect Jurkat migration towards CXCL12 (Figure 3 C). The Ras inhibitor shows toxicity 
in MCF-7 cells after 24 hours (data not shown) and is therefore not suitable for wound healing 
assays, even at lowered concentrations. Similarly the JAK2 and STAT3 inhibitors affect cell 
viability over 24 hours at 10 µM, at the lower concentration of 1 µM both inhibitors do not show 
any toxicity. Whereas the STAT3 inhibitor does not affect cell migration into the wound, the 
effect of the JAK2 inhibitor is less clear; there seems to be a slight trend to block migration, 
but it was not significant (Figure 3 D).  
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3.3 Src activation is vital for both breast cancer cell as well as leukemic cell migration.  
Another signalling cascade, which has been highlighted as being involved in CXCR4 induced 
migration, is the Raf/MEK/ERK network. Cells were pre-treated with SB203580, an inhibitor of 
p38 MAPK, PD98059, a small molecule inhibitor targeting MEK specifically or Bosutinib, a Src 
inhibitor. Blocking p38 MAPK, MEK and Src resulted in around 50% reduction in migration 
(Figure 4). This reduction in migrating cells is not a consequence of any toxicity of Bosutinib, 
as shown by MTS assays (Figure 4 D). Again, there are significant differences in MCF-7 cells. 
Even though the Src inhibitor Bosutinib completely blocked any migration of MCF-7 cells into 
the wound, both the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor SB203580 did not 
show a pronounced blocking of cell migration, however the wound in the SB203580 treated 
cells remained significantly larger than in the control cells (Figure 4 E, F). We verified the 
results obtained with Bosutinib with an siRNA approach. A knock down of Src prevents 
migration of Jurkat cells as well as the migration of MCF-7 cells in a wound-healing assay 
(Figure 5 A, B). The efficiency of knockdown was confirmed by Western blot analysis (Figure 
5 E). 
 
 
3.4 PI3K activation is important for leukemic cell migration but not in wound-healing 
assays.  
To further evaluate which signalling partners are involved in transducing receptor activation to 
cell migration, we used a second MEK inhibitor (SL327) as well as the well-established PI3K 
inhibitor (LY294002), Raf (L779450) and β-catenin (FH535) inhibitors and we also knocked 
down p85 PI3K using an siRNA approach (Figure 5 C,D,E,F). Whereas the knock down of 
PI3K in Jurkat and MCF-7 cells prevented migration significantly, the results with a small 
molecule antagonist LY294002 were less clear. The blockade of PI3K completely abolishes 
any migration in Jurkat cells and the other inhibitors led to a small, but significant decrease of 
migrating suspension cells (Figure 6). In the adherent MCF-7 cells there are some differences. 
Whereas the effect of blocking migration by L775450 is much more pronounced, LY294002 
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fails to show a significant effect on these cells (Figure 6 F). We verified that in Jurkat cells the 
migration towards CXCL12 is in response to CXCR4 with the use of a monoclonal antibody 
directed against CXCR4 which blocks migration (Figure 6 H). 
 
4. Discussion 
Chemokine receptor induced cell migration is a crucial step in metastasis of cancer as well as 
the inflammatory response [23]. Understanding the mechanisms of migration therefore can 
potentially provide novel therapeutic targets to prevent undesirable cell migration. The 
chemokine receptor CXCR4 has been of interest for a number of years, as it has been shown 
to be up-regulated in several cancers and its activation can lead to cancer cell metastasis [23, 
38-41]. Although numerous studies have investigated different aspects of the signalling 
cascades which are involved in the cell migration, some questions still remain unanswered. 
Furthermore there is conflicting evidence in the literature about the importance or involvement 
of downstream signalling partners in different systems [11, 27-29, 38, 42-44]. One problem is 
that most studies only characterised a small number of signalling molecules at any one time 
and since a whole variety of cell types/read-out systems and approaches were used, it can be 
expected that some of the data may contradict each other. We therefore set out to investigate 
the main signalling molecules that are thought to be of importance in CXCL12 induced 
migration in adherent cells versus suspension cells. One of the findings in our study is that 
there are indeed differences in which signalling molecules are important for cell migration of 
leukemic cells compared to adherent breast cancer cells. Both cell types used (the leukemic 
cell line Jurkat and the breast cancer cell line MCF-7) express CXCR4 and migrate towards 
CXCL12, however the signalling molecules show some intriguing differences. The two cell 
lines used express CXCR4 and blocking of CXCL12 binding to CXCR4 with the aid of a 
CXCR4 specific antibody prevents migration of cells, showing that CXCR4 is the main 
receptor, if not the only one on these cells to induce migration in response to CXCL12. 
Protein Kinase C (PKC) has been shown to have central roles in signalling in response to 
many extracellular ligands, and can influence many aspects of cell behaviour. Several groups 
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have shown that receptor desensitization is not necessarily based only on phosphorylation of 
agonist- occupied receptors by G-Protein coupled receptor kinases (GRK) but also can be 
caused by phosphorylation of receptors by second messenger-activated kinases such as 
Protein Kinase C, to attenuate receptor interaction with G-Proteins. Oppermann et al. [45] 
have shown the equivalence in importance of both GRK and second messengers PKC in 
phosphorylation of receptors. Second messenger-activated kinases, Protein Kinase A (PKA) 
and PKC potentially phosphorylate both the ligand bound GPCR and multiple other receptors 
in a heterologous manner [46]. There are a variety of studies that show that PKC isoforms are 
also important for cancer cell migration [10, 47] and indeed, a pan PKC inhibitor GF109203X 
completely blocks breast cancer cell migration towards CXCL12; however at the same 
concentration there is no effect on the migration of the leukemic suspension cells towards 
CXCL12. Instead GF109203X leads to a slight, if not significant, increase in migration. This 
agrees with a previous study of our lab, where we showed that the same PKC inhibitor does 
not block CCL3 induced migration in the suspension cells THP-1 [36]. We used a siRNA 
approach to confirm the results obtained with the small molecule antagonists, and indeed, a 
knock down of PKCα and PKCζ in MCF-7 cells completely abrogates any movement of the 
cells into the wound, confirming the results obtained with the PKC inhibitors. The picture in 
Jurkat cells is slightly more complicated. Both PKCα and PKCζ knockdowns result in a 
significant loss of migratory cells which is in stark contrast to the PKC inhibitor studies. We 
therefore speculate that there is a difference in usage of PKC in the two cell types. Whereas 
the MCF-7 cells need the catalytic activity of PKC (hence a small molecule antagonist as well 
as knock down prevents migration) in Jurkat cells it seems plausible, that it is not the kinase 
activity of PKC which is implicated in cell migration, it is rather the functionality of the other 
PKC domains. For example PKCs localizes in cells with cytoskeletal proteins (such as actin 
and tubulin) and true scaffolding proteins (such as caveolin) and might therefore be implicated 
in migration. It has also been shown that PKCs can be cleaved by caspases, generating a 
catalytically active kinase domain and a freed regulatory domain fragment that can act both 
as an inhibitor of the full-length enzyme and as an activator of certain signalling responses 
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[48]. Altogether the data in Jurkat cells are more complex, but they show a difference towards 
PKC use in MCF-7 cells and warrant further investigation. 
The JAK/STAT pathway has been implicated for being an essential pathway in cell migration 
for some time [49], however recent studies showed that some of the results could be due to 
the effects some inhibitors have on actin dynamics in cells [50, 51] or that JAK activation is 
not important for chemokine induced activation after all [30]. Using a variety of different 
JAK2/STAT3 inhibitors, we did not detect a significant effect of JAK2/STAT3 inhibition on 
migration in both leukemic or breast cancer cells.  
In keeping with the findings of other groups studying aspects of CXCL12 signalling in a variety 
of cell types [42, 52] Src kinase activation is critical migration in both leukemic and breast 
cancer cells. We have also confirmed that the Raf/MEK/ERK1/2 pathway plays an important 
role in leukemic cell migration with a somewhat diminished importance in breast cancer cells. 
Unlike Sobolik et al., who showed that in a 3D model, inhibition of PI3K reversed the 
aggressive phenotype of MCF-7 [53], we did not observe a significant effect of PI3K inhibition 
on wound-healing in a 2D model when using LY294002. Knock down of PI3K p85 expression 
in MCF-7 cells, abrogates any migration towards CXCL12 in the wound healing assay, 
confirming published studies. In Jurkat cells, PI3K inhibition significantly reduces cell 
migration, whether it is the use of LY294002 or the knock down of protein expression.  
Our study highlights that the cellular background can be important for the distinct signalling 
pathways used by the CXCR4 receptor and therefore a generalisation of how CXCR4 induces 
migration in different cell types and species should be avoided. There are quite a few 
similarities between the different cell types, however some subtle differences mean that there 
is the potential to block migration of specific cancer cell types when targeting metastases. 
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6. Figures and legends 
Figure 1: PKC and PKD activation is not essential for CXCL12 induced migration. A) 
Shows migratory response of Jurkat cells towards 1nM CXCL12 in untreated control cells or 
Staurosporine pre-treated cells. B) Cell migration towards 1nM CXCL12 in untreated control 
cells or GF109203x pre-treated cells. C) Cell migration towards 1nM CXCL12 in untreated 
control cells or CID755673 pre-treated cells. D) Cell migration towards 1nM CXCL12 in 
untreated control cells or Rottlerin pre-treated cells. E) Wound healing assay on MCF-7 cells 
in the presence or absence of Rottlerin or GF109203X. Cell migration was induced with 10 
nM CXCL12 and measured after 24 hours. F) Quantification of migration of cells into the 
wound. A number of 1 denotes no migration occurred whereas a number < 1 denotes cell 
migration. * denotes a significant difference towards to corresponding control (p≤0.05, One-
way ANOVA with a Bonferroni Multiple Comparison test as post-test). G) CXCR4 was 
visualised on Jurkat and MCF-7 cells by 12G5 mAb staining. Data shown are the mean ± SEM 
of at least 3 independent experiments.  
Figure 2: siRNA transfection into MCF-7 cells and Jurkat cells A) Wound healing assay 
on MCF-7 cells after transfection with scrambled control siRNA (sc siRNA) or PKCζ siRNA. 
Cell migration was induced with 10 nM CXCL12 and measured after 24 hours. B) Cell 
migration towards 1 nM CXCL12 in Jurkat cells after transfection with scrambled control siRNA 
(sc siRNA) or PKCζ siRNA. C) Wound healing assay on MCF-7 cells after transfection with 
scrambled control siRNA (sc siRNA) or PKCα siRNA. Cell migration was induced with 10 nM 
CXCL12 and measured after 24 hours. D) Cell migration towards 1 nM CXCL12 in Jurkat cells 
after transfection with scrambled control siRNA (sc siRNA) or PKCα siRNA. E, F) Western blot 
analysis of PKCζ and PKCα expression in MCF-7 after knockdown, β-actin acts as loading 
control. G) Western blot analysis of PKCα expression in Jurkat cells after knockdown, β-actin 
acts as loading control. Quantification of migration of cells into the wound. A number of 1 
denotes no migration occurred whereas a number < 1 denotes cell migration. ** denotes a 
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significant difference towards the corresponding control (**=p≤0.01, ***=p≤0.001, One-way 
ANOVA with a Bonferroni Multiple Comparison test as post-test). Data shown are the mean ± 
SEM of at least 3 independent experiments.  
 
Figure 3: Jak/STAT activation is not essential for CXCL12 induced migration. A) Shows 
migratory response of Jurkat cells towards 1nM CXCL12 in untreated control cells or AG490 
pre-treated cells, there is no significant differences between the inhibitor treated cells and 
control cells in the presence of CXCL12. B) Cell migration towards 1nM CXCL12 in untreated 
control cells or Stat VIII or Jak-2 pre-treated cells. C) Cell migration towards 1 nM CXCL12 in 
untreated control cells or Farnesylthiosalicylic acid pre-treated cells. Data shown are the mean 
± SEM of at least 3 experiments.  
 
Figure 4: CXCL12 induced migration depends on Src, p38 MAPK and MEK activation. 
A) Shows migratory response of Jurkat cells towards 1 nM CXCL12 in untreated control cells 
or SB203580 pre-treated cells. B) Cell migration towards 1 nM CXCL12 in untreated control 
cells or 25 µM PD98059 pre-treated cells. C) Cell migration towards 1 nM CXCL12 in untreated 
control cells or 2.5 µM Bosutinib pre-treated cells. Statistical analyses were performed using 
a one-way ANOVA with a Bonferroni multiple comparison test as post-test with *** showing a 
p value of ≤ 0.001. D) MTS assay in Jurkat cells with different concentrations of Bosutinib, as 
indicated. E) Wound healing assay on MCF-7 cells in the presence or absence of PD98059, 
SB203580 or Bosutinib. Cell migration was induced with 10 nM CXCL12 and measured after 
24 hours. F) Quantification of migration of cells into the wound. 1 denotes no migration 
occurred whereas a number < 1 denotes cell migration. * denotes a significant difference 
towards to inhibitor treated/untreated cells in the presence of CXCL12, (p≤0.05, One-way 
ANOVA with a Bonferroni Multiple Comparison test as post-test)Data shown are the mean ± 
SEM of at least 3 experiments.  
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Figure 5: siRNA transfection into MCF-7 cells and Jurkat cells A) Wound healing assay 
on MCF-7 cells after transfection with scrambled control siRNA (sc siRNA) or Src siRNA. Cell 
migration was induced with 10 nM CXCL12 and measured after 24 hours. B) Cell migration 
towards 1 nM CXCL12 in Jurkat cells after transfection with scrambled control siRNA (sc 
siRNA) or Src siRNA. C) Wound healing assay on MCF-7 cells after transfection with 
scrambled control siRNA (sc siRNA) or PI3K siRNA. Cell migration was induced with 10 nM 
CXCL12 and measured after 24 hours. D) Cell migration towards 1 nM CXCL12 in Jurkat cells 
after transfection with scrambled control siRNA (sc siRNA) or PI3K siRNA. E, F) Western blot 
analysis of Src and PI3K expression in MCF-7 after knockdown, β-actin acts as loading 
control. G) Western blot analysis of Src expression in Jurkat cells after knockdown, β-actin 
acts as loading control. Quantification of migration of cells into the wound. A number of 1 
denotes no migration occurred whereas a number < 1 denotes cell migration. ** denotes a 
significant difference towards the corresponding control (**=p≤0.01, ***=p≤0.001, One-way 
ANOVA with a Bonferroni Multiple Comparison test as post-test). Data shown are the mean ± 
SEM of at least 3 independent experiments. 
 
Figure 6: CXCL12 induced migration depends on Raf, MEK, PI3K and β-catenin 
activation. A) Shows migratory response of Jurkat cells towards 1 nM CXCL12 in untreated 
control cells or L779450 pre-treated cells. B) Cell migration towards 1 nM CXCL12 in untreated 
control cells or SL327 pre-treated cells. C) Cell migration towards 1 nM CXCL12 in untreated 
control cells or FH535 pre-treated cells. E) Cell migration towards 1 nM CXCL12 in untreated 
control cells or LY294002 pre-treated cells F) Wound healing assay on MCF-7 cells in the 
presence or absence of L779450 and LY294002. Cell migration was induced with 10 nM 
CXCL12 and measured after 24 hours. G) Quantification of migration of cells into the wound. 
1 denotes no migration occurred whereas a number < 1 denotes cell migration. *** denotes a 
significant difference towards to inhibitor treated/untreated cells in the presence of CXCL12, 
(p≤0.001, n.s is not significant, One-way ANOVA with a Bonferroni Multiple Comparison test 
as post-test). H) Incubation with CXCR4 specific mAB before inducement of migration towards 
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1nM CXCL12 significantly blocks migration. Statistical analyses were performed using a one-
way ANOVA with a Bonferroni multiple comparison test as post-test with *** showing a p value 
of ≤ 0.001. Data shown are the mean ± SEM of at least 3 independent experiments.  
 
 
Figure 7: Overview of signalling cascade in Jurkat and MCF-7 cells 
Schematic overview of signalling cascades involved in migration of cells towards CXCL12. 
 
 
 
7. References 
[1] Zhang XHF, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, 
Massague J, Cancer cell. 2009;16:67-78. 
[2] Wang SE, J Signal Transduct. 2011;2011:804236. 
[3] de Lourdes Perim A, Amarante MK, Guembarovski RL, de Oliveira CEC, 
Watanabe MAE, Cell Mol Life Sci. 2015;72:1715-1723. 
[4] Reikvam H, Hauge M, Brenner AK, Hatfield KJ, Bruserud Ø, Expert review of 
hematology. 2015;0:1-15. 
[5] Hanahan D, Weinberg RA, Cell. 2011;144:646-674. 
[6] Polyak K, Weinberg RA, Nature reviews. Cancer. 2009;9:265-273. 
[7] Klymkowsky MW, Savagner P, Am J Pathol. 2009;174:1588-1593. 
[8] Zlotnik A, Int J Cancer. 2006;119:2026-2029. 
[9] Vandercappellen J, Van Damme J, Struyf S, Cancer Lett. 2008;267:226-244. 
[10] Chuang JY, Yang WH, Chen HT, Huang CY, Tan TW, Lin YT, Hsu CJ, Fong 
YC, Tang CH, J Cell Physiol. 2009;220:418-426. 
[11] Kirui JK, Xie Y, Wolff DW, Jiang H, Abel PW, Tu Y, J Pharmacol Exp Ther. 
2010;333:393-403. 
[12] Raman D, Sobolik-Delmaire T, Richmond A, Exp Cell Res. 2011;317:575-589. 
[13] Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker 
N, Volkman BF, Dwinell MB, Proc Natl Acad Sci U S A. 2011;108:17655-17660. 
[14] Konoplev S, Lin P, Yin CC, Lin E, Nogueras Gonzalez GM, Kantarjian HM, 
Andreeff M, Medeiros LJ, Konopleva M, Clinical lymphoma, myeloma & leukemia. 
2013;13:686-692. 
[15] Teicher BA, Fricker SP, Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2010;16:2927-2931. 
[16] Patrussi L, Capitani N, Cannizzaro E, Finetti F, Lucherini OM, Pelicci PG, 
Baldari CT, Cell Death Dis. 2014;5:e1068. 
[17] Sison EAR, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P, 
Oncotarget. 2014;5:8947-8958. 
 19 
[18] Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, Nakamura T, 
Tanoue H, Ito H, Yugami M, Miyata K, Morinaga J, Horiguchi H, Motokawa I, Terada 
K, Morioka MS, Manabe I, Iwase H, Mizuta H, Oike Y, Sci Rep. 2015;5:9170. 
[19] Cane S, Ponnappan S, Ponnappan U, Aging Cell. 2012;11:651-658. 
[20] Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB, Dwinell MB, PloS 
one. 2014;9:e90400. 
[21] Nibbs RJB, Graham GJ, Nature reviews Immunology. 2013;13:815-829. 
[22] Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, 
Minina S, Wilson D, Xu Q, Raz E, Cell. 2008;132:463-473. 
[23] Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham 
GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, 
Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot 
A, Sozzani S, Thelen M, Yoshie O, Zlotnik A, Pharmacological reviews. 2014;66:1-
79. 
[24] Coggins NL, Trakimas D, Chang SL, Ehrlich A, Ray P, Luker KE, Linderman JJ, 
Luker GD, PLoS One. 2014;9:e98328. 
[25] Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T, 
Baleux F, Gunera-Saad N, Arenzana-Seisdedos F, Bachelerie F, Blood. 
2008;112:34-44. 
[26] Sun Y, Cheng Z, Ma L, Pei G, J Biol Chem. 2002;277:49212-49219. 
[27] Delgado-Martin C, Escribano C, Pablos JL, Riol-Blanco L, Rodriguez-Fernandez 
JL, J Biol Chem. 2011;286:37222-37236. 
[28] Ong ST, Freeley M, Skubis-Zegadlo J, Fazil MH, Kelleher D, Fresser F, Baier G, 
Verma NK, Long A, J Biol Chem. 2014;289:19420-19434. 
[29] Petit I, Goichberg P, Spiegel A, Peled A, Brodie C, Seger R, Nagler A, Alon R, 
Lapidot T, J Clin Invest. 2005;115:168-176. 
[30] Holgado BL, Martinez-Munoz L, Sanchez-Alcaniz JA, Lucas P, Perez-Garcia V, 
Perez G, Rodriguez-Frade JM, Nieto M, Marin O, Carrasco YR, Carrera AC, Alvarez-
Dolado M, Mellado M, Molecular neurobiology. 2013;48:217-231. 
[31] Opdam FJ, Kamp M, de Bruijn R, Roos E, Oncogene. 2004;23:6647-6653. 
[32] Pfeiffer M, Hartmann TN, Leick M, Catusse J, Schmitt-Graeff A, Burger M, Br J 
Cancer. 2009;100:1949-1956. 
[33] Cory AH, Owen TC, Barltrop JA, Cory JG, Cancer Commun. 1991;3:207-212. 
[34] Berridge MV, Tan AS, Arch Biochem Biophys. 1993;303:474-482. 
[35] Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG, Br J 
Pharmacol. 2002;135:1033-1043. 
[36] Moyano Cardaba C, Jacques RO, Barrett JE, Hassell KM, Kavanagh A, 
Remington FC, Tse T, Mueller A, Biochem Biophys Res Commun. 2012;418:17-21. 
[37] Soltoff SP, Trends Pharmacol Sci. 2007;28:453-458. 
[38] Dillenburg-Pilla P, Patel V, Mikelis CM, Zarate-Blades CR, Doci CL, 
Amornphimoltham P, Wang Z, Martin D, Leelahavanichkul K, Dorsam RT, 
Masedunskas A, Weigert R, Molinolo AA, Gutkind JS, FASEB J. 2015;29:1056-1068. 
[39] Sun Y, Mao X, Fan C, Liu C, Guo A, Guan S, Jin Q, Li B, Yao F, Jin F, Tumour 
biology : the journal of the International Society for Oncodevelopmental Biology and 
Medicine. 2014;35:7765-7773. 
[40] Mukherjee D, Zhao J, American journal of cancer research. 2013;3:46-57. 
[41] Ramsey DM, McAlpine SR, Bioorg Med Chem Lett. 2013;23:20-25. 
[42] Cheng M, Huang K, Zhou J, Yan D, Tang YL, Zhao TC, Miller RJ, Kishore R, 
Losordo DW, Qin G, Journal of molecular and cellular cardiology. 2015;81:49-53. 
[43] Wang Z, Ma Q, Med Hypotheses. 2007;69:816-820. 
 20 
[44] Vicente-Manzanares M, Cabrero JR, Rey M, Perez-Martinez M, Ursa A, Itoh K, 
Sanchez-Madrid F, J Immunol. 2002;168:400-410. 
[45] Oppermann M, Freedman NJ, Alexander RW, Lefkowitz RJ, J Biol Chem. 
1996;271:13266-13272. 
[46] Pollok-Kopp B, Schwarze K, Baradari VK, Oppermann M, J Biol Chem. 
2003;278:2190-2198. 
[47] Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D, Oncogene. 2011;30:323-
333. 
[48] Steinberg SF, Physiol Rev. 2008;88:1341-1378. 
[49] Brown S, Zeidler MP, Hombria JE, Dev Dyn. 2006;235:958-966. 
[50] Knecht DA, LaFleur RA, Kahsai AW, Argueta CE, Beshir AB, Fenteany G, PLoS 
ONE. 2010;5:e14039. 
[51] Khabbazi S, Jacques RO, Moyano Cardaba C, Mueller A, Cell Biochem Funct. 
2013;31:312-318. 
[52] De Luca A, D'Alessio A, Gallo M, Maiello MR, Bode AM, Normanno N, Cell 
cycle. 2014;13:148-156. 
[53] Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A, Mol Biol Cell. 
2014;25:566-582. 
 
 
 21
 
 22
 
 23
 
m
ea
n 
ba
sa
l
CX
Cl1
2
m
ea
n 
ba
sa
l
CX
CL
12
0
100
200
300
control
**
AG490
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
m
ea
n 
ba
sa
l
CX
Cl1
2
m
ea
n 
ba
sa
l
CX
Cl1
2
0
100
200
300
400
CXCl12
Farnesyl thiosalicylic acid
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
m
ea
n 
ba
sa
l
CX
Cl1
2
m
ea
n 
ba
sa
l
CX
Cl1
2
m
ea
n 
ba
sa
l
CX
Cl1
2
0
100
200
300
400
control
Stat VIII
JAK-2
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
a) b)
c)
Figure 3
d)
 24
 
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
50
100
150
200
250
***
control
SB203580
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
20
40
60
80
100
120
140
160
***
control
PD98059
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
Co
ntr
ol Mµ5 
Mµ
2.5
 
Mµ
1.2
5 
0.0
0.5
1.0
1.5
2.0
*
control
Bosutinib
A
b
s
o
r
b
a
n
c
e
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
100
200
300
400
500
***
control
Bosutinib
M
i
g
r
a
t
i
n
g
 
c
e
l
l
s
 
/
 
1
0
4
m
L
-
1
a)
c)
d)
b)
Figure 4
e)
f)
0 hours
24 hours
CXCL12 - + + + +
PD98059 - - + - -
SB203580 - - - + -
Bosutinib - - - - +
 25
 
 
26
 
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
10
0
20
0
30
0
c
o
n
tr
o
l
L7
79
45
0
*
Migrating cells / 10
4
mL
-1
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
10
0
20
0
30
0
*
*
*
c
o
n
tr
o
l
SL
32
7
Migrating cells x 10
4
mL
-1
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
10
0
20
0
30
0
*
*
co
nt
ro
l
FH
53
5
Migrating cells / 10
4
mL
-1
a
)
c)
b
)
F
ig
u
re
 6
co
nt
ro
l
C
XC
L1
2
co
nt
ro
l
C
X
C
L1
2
co
nt
ro
l
C
X
C
L1
2
e
)
f)
g
)
0
 h
o
u
rs
2
4
 h
o
u
rs
C
X
C
L1
2
-
+
+
+
L7
7
9
4
5
0
-
-
+
-
LY
2
9
4
0
0
2
-
-
-
+
m
ea
n 
ba
sa
l
CX
CL
12
m
ea
n 
ba
sa
l
CX
CL
12
0
10
0
20
0
30
0
40
0
50
0
*
*
*
co
n
tro
l
LY
29
40
02
Migrating cells / 10
4
mL
-1
C
XC
L1
2 
C
X
C
L1
2 
m
ea
n 
ba
sa
l
m
ea
n 
ba
sa
l
Migrating cells / 10
4
mL
-1
h
)
 27
 
